Purine salvage promotes treatment resistance in H3K27M-mutant diffuse midline glioma.
Diffuse midline glioma
H3K27M
Purine metabolism
Radiation therapy resistance
Journal
Cancer & metabolism
ISSN: 2049-3002
Titre abrégé: Cancer Metab
Pays: England
ID NLM: 101607582
Informations de publication
Date de publication:
09 Apr 2024
09 Apr 2024
Historique:
received:
01
09
2023
accepted:
21
03
2024
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
9
4
2024
Statut:
epublish
Résumé
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are a fatal form of brain cancer. These tumors often carry a driver mutation on histone H3 converting lysine 27 to methionine (H3K27M). DMG-H3K27M are characterized by altered metabolism and resistance to standard of care radiation (RT) but how the H3K27M mediates the metabolic response to radiation and consequent treatment resistance is uncertain. We performed metabolomics on irradiated and untreated H3K27M isogenic DMG cell lines and observed an H3K27M-specific enrichment for purine synthesis pathways. We profiled the expression of purine synthesis enzymes in publicly available patient data and our models, quantified purine synthesis using stable isotope tracing, and characterized the in vitro and in vivo response to de novo and salvage purine synthesis inhibition in combination with RT. DMG-H3K27M cells activate purine metabolism in an H3K27M-specific fashion. In the absence of genotoxic treatment, H3K27M-expressing cells have higher relative activity of de novo synthesis and apparent lower activity of purine salvage demonstrated via stable isotope tracing of key metabolites in purine synthesis and by lower expression of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), the rate-limiting enzyme of purine salvage into IMP and GMP. Inhibition of de novo guanylate synthesis radiosensitized DMG-H3K27M cells in vitro and in vivo. Irradiated H3K27M cells upregulated HGPRT expression and hypoxanthine-derived guanylate salvage but maintained high levels of guanine-derived salvage. Exogenous guanine supplementation decreased radiosensitization in cells treated with combination RT and de novo purine synthesis inhibition. Silencing HGPRT combined with RT markedly suppressed DMG-H3K27M tumor growth in vivo. Our results indicate that DMG-H3K27M cells rely on highly active purine synthesis, both from the de novo and salvage synthesis pathways. However, highly active salvage of free purine bases into mature guanylates can bypass inhibition of the de novo synthetic pathway. We conclude that inhibiting purine salvage may be a promising strategy to overcome treatment resistance in DMG-H3K27M tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are a fatal form of brain cancer. These tumors often carry a driver mutation on histone H3 converting lysine 27 to methionine (H3K27M). DMG-H3K27M are characterized by altered metabolism and resistance to standard of care radiation (RT) but how the H3K27M mediates the metabolic response to radiation and consequent treatment resistance is uncertain.
METHODS
METHODS
We performed metabolomics on irradiated and untreated H3K27M isogenic DMG cell lines and observed an H3K27M-specific enrichment for purine synthesis pathways. We profiled the expression of purine synthesis enzymes in publicly available patient data and our models, quantified purine synthesis using stable isotope tracing, and characterized the in vitro and in vivo response to de novo and salvage purine synthesis inhibition in combination with RT.
RESULTS
RESULTS
DMG-H3K27M cells activate purine metabolism in an H3K27M-specific fashion. In the absence of genotoxic treatment, H3K27M-expressing cells have higher relative activity of de novo synthesis and apparent lower activity of purine salvage demonstrated via stable isotope tracing of key metabolites in purine synthesis and by lower expression of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), the rate-limiting enzyme of purine salvage into IMP and GMP. Inhibition of de novo guanylate synthesis radiosensitized DMG-H3K27M cells in vitro and in vivo. Irradiated H3K27M cells upregulated HGPRT expression and hypoxanthine-derived guanylate salvage but maintained high levels of guanine-derived salvage. Exogenous guanine supplementation decreased radiosensitization in cells treated with combination RT and de novo purine synthesis inhibition. Silencing HGPRT combined with RT markedly suppressed DMG-H3K27M tumor growth in vivo.
CONCLUSIONS
CONCLUSIONS
Our results indicate that DMG-H3K27M cells rely on highly active purine synthesis, both from the de novo and salvage synthesis pathways. However, highly active salvage of free purine bases into mature guanylates can bypass inhibition of the de novo synthetic pathway. We conclude that inhibiting purine salvage may be a promising strategy to overcome treatment resistance in DMG-H3K27M tumors.
Identifiants
pubmed: 38594734
doi: 10.1186/s40170-024-00341-7
pii: 10.1186/s40170-024-00341-7
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11Subventions
Organisme : NCI NIH HHS
ID : 5T32CA140044-13
Pays : United States
Organisme : NCI NIH HHS
ID : F32CA260735
Pays : United States
Organisme : NCI NIH HHS
ID : K08CA234416
Pays : United States
Organisme : NIH HHS
ID : R01CA240515
Pays : United States
Organisme : NINDS NIH HHS
ID : R21NS123879-01
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica. 2016;131(6):803–20.
pubmed: 27157931
doi: 10.1007/s00401-016-1545-1
Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, et al. Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell. 2017;32(4):520-37.e5.
pubmed: 28966033
pmcid: 5637314
doi: 10.1016/j.ccell.2017.08.017
Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Sci Transl Med. 2019;11(519):eaaw0064.
pubmed: 31748226
pmcid: 7132630
doi: 10.1126/scitranslmed.aaw0064
Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E, Jacob K, et al. Driver mutations in histone H33 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226–31.
pubmed: 22286061
doi: 10.1038/nature10833
Himes BT, Zhang L, Daniels DJ. Treatment strategies in diffuse midline gliomas with the H3K27M mutation: the role of convection-enhanced delivery in overcoming anatomic challenges. Front Oncol. 2019;9:31.
pubmed: 30800634
pmcid: 6375835
doi: 10.3389/fonc.2019.00031
Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015;21(6):555–9.
pubmed: 25939062
pmcid: 4862411
doi: 10.1038/nm.3855
Liu SJ, Malatesta M, Lien BV, Saha P, Thombare SS, Hong SJ, et al. CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. Genome Biol. 2020;21(1):83.
pubmed: 32234056
pmcid: 7110660
doi: 10.1186/s13059-020-01995-4
Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys. 1999;43(5):959–64.
pubmed: 10192340
doi: 10.1016/S0360-3016(98)00501-X
Jansen MH, van VeldhuijzenZanten SE, Sanchez Aliaga E, Heymans MW, Warmuth-Metz M, Hargrave D, et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol. 2015;17(1):160–6.
pubmed: 24903904
doi: 10.1093/neuonc/nou104
Gardner SL, Allen JC, Zaky WT, Odia Y, Daghistani D, Khatib Z, et al. ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma. J Clin Oncol. 2019;37(15_suppl):10046.
doi: 10.1200/JCO.2019.37.15_suppl.10046
Nikolaev A, Fiveash JB, Yang ES. Combined targeting of mutant p53 and Jumonji family histone demethylase augments therapeutic efficacy of radiation in H3K27M DIPG. Int J Mol Sci. 2020;21(2):490.
pubmed: 31940975
pmcid: 7014308
doi: 10.3390/ijms21020490
Pachocki CJ, Hol EM. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. J Neuroinflammation. 2022;19(1):276.
pubmed: 36403059
pmcid: 9675250
doi: 10.1186/s12974-022-02630-8
Werbrouck C, Evangelista CCS, Lobón-Iglesias MJ, Barret E, Le Teuff G, Merlevede J, et al. TP53 pathway alterations drive radioresistance in diffuse intrinsic pontine gliomas (DIPG). Clin Cancer Res. 2019;25(22):6788–800.
pubmed: 31481512
doi: 10.1158/1078-0432.CCR-19-0126
Zhou W, Wahl DR. Metabolic abnormalities in glioblastoma and metabolic strategies to overcome treatment resistance. Cancers. 2019;11(9):1231.
pubmed: 31450721
pmcid: 6770393
doi: 10.3390/cancers11091231
Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, Garcia-Fabiani MB, et al. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019;11(479):eaaq1427.
pubmed: 30760578
pmcid: 6400220
doi: 10.1126/scitranslmed.aaq1427
Zhou W, Yao Y, Scott AJ, Wilder-Romans K, Dresser JJ, Werner CK, et al. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nat Commun. 2020;11(1):3811.
pubmed: 32732914
pmcid: 7393131
doi: 10.1038/s41467-020-17512-x
Guo F, Li J, Du W, Zhang S, O’Connor M, Thomas G, et al. mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells. Leukemia. 2013;27(10):2040–6.
pubmed: 23538752
pmcid: 4225699
doi: 10.1038/leu.2013.93
Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones DTW, Kool M, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell. 2013;24(5):660–72.
pubmed: 24183680
doi: 10.1016/j.ccr.2013.10.006
Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, et al. Pervasive H3K27 acetylation leads to ERV expression and a therapeutic vulnerability in H3K27M gliomas. Cancer Cell. 2019;35(5):782-97.e8.
pubmed: 31085178
pmcid: 6521975
doi: 10.1016/j.ccell.2019.04.004
Harutyunyan AS, Krug B, Chen H, Papillon-Cavanagh S, Zeinieh M, De Jay N, et al. H3K27M induces defective chromatin spread of PRC2-mediated repressive H3K27me2/me3 and is essential for glioma tumorigenesis. Nat Commun. 2019;10(1):1262.
pubmed: 30890717
pmcid: 6425035
doi: 10.1038/s41467-019-09140-x
Harutyunyan AS, Chen H, Lu T, Horth C, Nikbakht H, Krug B, et al. H3K27M in gliomas causes a one-step decrease in H3K27 methylation and reduced spreading within the constraints of H3K36 methylation. Cell Rep. 2020;33(7):108390.
pubmed: 33207202
pmcid: 7703850
doi: 10.1016/j.celrep.2020.108390
Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444–50.
pubmed: 24705251
pmcid: 4056452
doi: 10.1038/ng.2938
Larson JD, Kasper LH, Paugh BS, Jin H, Wu G, Kwon CH, et al. Histone H3.3 K27M accelerates spontaneous brainstem glioma and drives restricted changes in bivalent gene expression. Cancer Cell. 2019;35(1):140-55.e7.
pubmed: 30595505
doi: 10.1016/j.ccell.2018.11.015
Chung C, Sweha SR, Pratt D, Tamrazi B, Panwalkar P, Banda A, et al. Integrated metabolic and epigenomic reprograming by H3K27M mutations in diffuse intrinsic pontine gliomas. Cancer Cell. 2020;38(3):334-49.e9.
pubmed: 32795401
pmcid: 7494613
doi: 10.1016/j.ccell.2020.07.008
Pal S, Kaplan JP, Nguyen H, Stopka SA, Savani MR, Regan MS, et al. A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma. Cancer Cell. 2022;40(9):957-72.e10.
pubmed: 35985342
pmcid: 9575661
doi: 10.1016/j.ccell.2022.07.012
Golbourn BJ, Halbert ME, Halligan K, Varadharajan S, Krug B, Mbah NE, et al. Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. Nat Cancer. 2022;3(5):629–48.
pubmed: 35422502
pmcid: 9551679
doi: 10.1038/s43018-022-00348-3
Tsoli M, Liu J, Franshaw L, Shen H, Cheng C, Jung M, et al. Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma. Oncotarget. 2018;9(7):7541–56.
pubmed: 29484131
pmcid: 5800923
doi: 10.18632/oncotarget.24045
Jessa S, Mohammadnia A, Harutyunyan AS, Hulswit M, Varadharajan S, Lakkis H, et al. K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. Nat Genet. 2022;54(12):1865–80.
pubmed: 36471070
pmcid: 9742294
doi: 10.1038/s41588-022-01205-w
Kerk SA, Lin L, Myers AL, Sutton DJ, Andren A, Sajjakulnukit P, et al. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Elife. 2022;11:e73245.
pubmed: 35815941
pmcid: 9328765
doi: 10.7554/eLife.73245
Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, et al. MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49(W1):W388-w96.
pubmed: 34019663
pmcid: 8265181
doi: 10.1093/nar/gkab382
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
pubmed: 22588877
doi: 10.1158/2159-8290.CD-12-0095
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.
pubmed: 23550210
pmcid: 4160307
doi: 10.1126/scisignal.2004088
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
pubmed: 21376230
doi: 10.1016/j.cell.2011.02.013
Cruz-Gregorio A, Martínez-Ramírez I, Pedraza-Chaverri J, Lizano M. Reprogramming of energy metabolism in response to radiotherapy in head and neck squamous cell carcinoma. Cancers (Basel). 2019;11(2):182.
pubmed: 30764513
doi: 10.3390/cancers11020182
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.
pubmed: 13298683
doi: 10.1126/science.123.3191.309
Kunkel M, Moergel M, Stockinger M, Jeong JH, Fritz G, Lehr HA, et al. Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol. 2007;43(8):796–803.
pubmed: 17207657
doi: 10.1016/j.oraloncology.2006.10.009
Zhou W, Zhao Z, Lin A, Yang JZ, Xu J, Wilder-Romans K, et al. GTP signaling links metabolism, DNA Repair, and responses to genotoxic stress. Cancer Discov. 2024;14(1):158–75.
pubmed: 37902550
doi: 10.1158/2159-8290.CD-23-0437
Shireman JM, Atashi F, Lee G, Ali ES, Saathoff MR, Park CH, et al. De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. Brain. 2021;144(4):1230–46.
pubmed: 33855339
pmcid: 8105035
doi: 10.1093/brain/awab020
Lulla RR, Saratsis AM, Hashizume R. Mutations in chromatin machinery and pediatric high-grade glioma. Sci Adv. 2016;2(3):e1501354.
pubmed: 27034984
pmcid: 4803494
doi: 10.1126/sciadv.1501354
Umemura Y, Sun Y, Junck L, Leung D, Kim M, Al-Holou W, et al. DDRE-19. PHASE 0/I TRIAL OF MYCOPHENOLATE MOFETIL COMBINED WITH RADIATION TO OVERCOME GLIOBLASTOMA TREATMENT RESISTANCE BY TARGETING DE-NOVO PURINE METABOLISM. Neurooncol Adv. 3: © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.; 2021. p. i10.
Zhao G, Newbury P, Ishi Y, Chekalin E, Zeng B, Glicksberg BS, et al. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma. Acta Neuropathol Commun. 2022;10(1):150.
pubmed: 36274161
pmcid: 9590174
doi: 10.1186/s40478-022-01463-z
Lin GL, Monje M. A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma (DIPG). J Vis Exp. 2017;1421:55360.
Wilde BR, Chakraborty N, Matulionis N, Hernandez S, Ueno D, Gee ME, et al. FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancer. Cancer Discov. 2023;13(9):2072–89.
pubmed: 37255402
pmcid: 10527600
doi: 10.1158/2159-8290.CD-22-0874
Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993;268(36):27286–90.
pubmed: 7903306
doi: 10.1016/S0021-9258(19)74247-1
Deguchi Y, Yokoyama Y, Sakamoto T, Hayashi H, Naito T, Yamada S, et al. Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier. Life Sci. 2000;66(7):649–62.
pubmed: 10794520
doi: 10.1016/S0024-3205(99)00637-2
Hocková D, Keough DT, Janeba Z, Wang TH, de Jersey J, Guddat LW. Synthesis of novel N-branched acyclic nucleoside phosphonates as potent and selective inhibitors of human, Plasmodium falciparum and Plasmodium vivax 6-oxopurine phosphoribosyltransferases. J Med Chem. 2012;55(13):6209–23.
pubmed: 22725979
doi: 10.1021/jm300662d
Bettio LE, Gil-Mohapel J, Rodrigues AL. Guanosine and its role in neuropathologies. Purinergic Signal. 2016;12(3):411–26.
pubmed: 27002712
pmcid: 5023624
doi: 10.1007/s11302-016-9509-4
Seegmiller JE, Rosenbloom FM, Kelley WN. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science. 1967;155(3770):1682–4.
pubmed: 6020292
doi: 10.1126/science.155.3770.1682